Barclays PLC Capricor Therapeutics, Inc. Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 89,650 shares of CAPR stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
89,650
Previous 36,296
147.0%
Holding current value
$1.18 Million
Previous $552,000
124.28%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CAPR
# of Institutions
133Shares Held
16MCall Options Held
1.73MPut Options Held
1.71M-
Vanguard Group Inc Valley Forge, PA2.28MShares$29.9 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.25MShares$29.5 Million0.17% of portfolio
-
State Street Corp Boston, MA2.21MShares$29 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.63MShares$21.4 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA879KShares$11.5 Million0.0% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $320M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...